BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE
—Expands BioCryst portfolio of targeted oral prophylactic therapy options to meet patients’ individual needs and preferences—
Covered in this story
What has happened since
- Haemonetics Corp is down 0.8% since this was published.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $HAE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Haemonetics Corp →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.